Brain and CNS Clinical Network Group (CNG)

Transcription

1 Brain and CNS Clinical Network Group (CNG) Annual Report This Annual Report has been agreed by: Title Name Date Agreed Brain and CNS CNG Chair CMSCN Cancer Clinical Lead CWW Area Team Medical Director Brian Haylock Chris Warburton Kieran Murphy Agreed on behalf of the Brain and CNS CNG by the Chair Brain and CNS CNG Annual Report (Approved August 2014) Page 1 of 6

2 Contents 1.0 Structure and function of the CNG Coordination of care/patient pathways Patient experience... Error! Bookmark not defined. 4.0 Clinical outcomes/indicators... Error! Bookmark not defined. 5.0 Good Practice... Error! Bookmark not defined. 6.0 Concerns... 4 Appendix 1.0: CNG (Core Membership) : CNG (Extended Membership)... Error! Bookmark not defined. Appendix 2.0: Clinical Trials Data... 6 Brain and CNS CNG Annual Report (Approved August 2014) Page 2 of 6

3 1.0 Structure and function of the CNG This annual report for Cheshire & Merseyside Strategic Clinical Network (CMSCN) Brain and CNS Clinical Network Group (CNG) relates to the operational period 1st April 2013 to 31st March This report describes the work carried out across the Network over the course of the year. The CNG supports the overall aims of the network by facilitating collaboration between providers and users of brain and CNS cancer services in order to provide seamless care based on best practice. The Group is the main source of clinical advice to the CMSCN Cancer Steering Group & Oversight Group. The CNG is a busy, productive multi-professional group with strong engagement from participating Trusts and MDTs. Group membership is fully compliant with peer review requirements. The CNG s Constitution is reviewed & updated on an annual basis. Content includes: Terms of Reference Communication requirements Key Responsibilities 14-1C-104k The CNG met twice during the reporting period. The national re-configuration of clinical networks has impacted significantly on the capacity to support clinical network groups through the transition period and the Chair of the Network Group stepped down in November 2013 with a subsequent hiatus until a replacement chair was appointed. Appendix 1.0 contains a summary record of meeting dates & attendance. 14-1C-105k - The CNG has produced a work programme, which reflects the strategic ambitions of CMSCN. This has been agreed with the Network Cancer Clinical Lead & Medical Director of Cheshire, Wirral & Warrington Area Team. 2.0 Coordination of care/patient pathways The network group has reviewed & updated its clinical guidelines during this reporting period. These reflect all relevant modalities, including: Imaging Pathology Surgical Management Chemotherapy Radiotherapy The network group agreed the list of chemotherapy treatment algorithms with Clatterbridge Cancer Centre The CNG has agreed pathways for: Teenage and young adults: covering initial management and follow up on completion of first line treatment Brain and CNS CNG Annual Report (Approved August 2014) Page 3 of 6

4 3.0 Patient experience 14-1C-116k Results of the 2013 National Cancer Patient Experience Survey were released at the end of August Nationally 730 brain and CNS patients responded to the survey but only 10 surveys were completed locally. The results of the survey were discussed at the meeting on the 21 st November 2013, a CQUIN has been developed for contact with a CNS and the results are being collated and a patient survey on pituitary patients is to be carried out in The CNG has active patient representation through the Brain Tumour Charity who raise a number of service related issues through the group with practical positive results. The introduction of patients passports has been met positively by patients supporting them in giving information once and not having to repeat details; feedback on changes within the treatment centre have influenced positive change around car parking and outpatient management systems 4.0 Clinical outcomes/indicators 14-1C-117k The CNG co-ordinated an audit in ensuring all patients were discussed at the Pituitary MDT following peer review feedback 14-1C-118k Clinical Trials were reported at each meeting and the results of the MCCRN study See Appendix 2 See appendix Good practice Developing the neuro-rehabilitation operational policy has required cross network involvement and a comprehensive directory compiled 6.0 Concerns The group not having met consistently over the past year due to Network constraints has impacted on the ability to keep up the momentum of the group. Additional support has been secured and a new chair identified which will hopefully support the group in going forward Brain and CNS CNG Annual Report (Approved August 2014) Page 4 of 6

5 Appendix 1.0: CNG (Membership) Brain and CNS CNG - Core Membership Name Organisation Role Brian Haylock Clatterbridge Cancer Centre Consultant Oncologist AT Aditya Shenoy Clatterbridge Cancer Centre Consultant Oncologist AT Hannah Roberts Clatterbridge Cancer Centre Occupational Therapist AT AT Helen Parton Clatterbridge Cancer Centre CNS AT Jackie Ogden Clatterbridge Cancer Centre Occupational Therapist AT Andrew Brodbelt (chair) The Walton Centre Consultant Neurosurgeon AT AT Anna Crofton The Walton Centre CNS AT Emma Chadwick The Walton Centre Assistant Divisional Manager AT AT Colin Pinder The Walton Centre Consultant in neurorehabiliation Emily Gerrans The Walton Centre Physiotherapist In Patient AT AT Maneesh Bhojak The Walton Centre Consultant Neuroradiologist Michael Jenkinson The Walton Centre Consultant Neurosurgeon, brain and Spinal tumours MDT Chair AT Barry Pizer Alder Hey Childrens Hospital Consultant Paediatric Oncologist Helen Paisley Alder Hey Childrens Hospital Paediatric Oncology Nurse Gail O Halloran Aintree University Hospital NHS Speech Therapist AT Foundation Trust / The Walton Centre James Brown Aintree University Hospital NHS ENT Surgeon, Skull Base MDT Chair AT Foundation Trust Niladri Ghosal Betsi Cadwallader Consultant Oncologist AT AT Tom Livingstone Brain Tumour UK Ambassador AT AT Tony Murphy Patient Representative AT Vicki Morana Patient Representative AT AT Linda Deveruex Cheshire & Merseyside Strategic Quality Improvement Lead AT D Clinical Networks Sarah Griffiths Cheshire & Merseyside Strategic Clinical Networks Network Assistant D D Brain and CNS CNG Annual Report (Approved August 2014) Page 5 of 6

6 KEY: AT = Attended AP = Apologies sent D = Deputy sent R = Remote Attendance (TC/VC) Appendix 2.0: Clinical Trials Data Brain Trials Report July 14 FINAL (data s Brain and CNS CNG Annual Report (Approved August 2014) Page 6 of 6